Anixa Biosciences(ANIX) Prnewswire·2024-10-31 12:15Company Overview - Anixa Biosciences Inc is a clinical-stage biotechnology company focused on the treatment and prevention of cancer [2] - The company's therapeutic portfolio includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center using CER-T technology [2] - Anixa's vaccine portfolio includes breast cancer and ovarian cancer vaccines developed with Cleveland Clinic, as well as additional cancer vaccines targeting lung, colon, and prostate cancers [2] - The company employs a unique business model of partnering with world-renowned research institutions for technology development and commercialization [2] Upcoming Events - Anixa will present at the Sidoti Micro-Cap Virtual Conference on November 14, 2024 at 1:00pm ET [1] - The presentation will be available via Zoom and 1x1 meetings are open to all registered investors [1] - The company will release updated data from its breast cancer clinical trial on November 8, 2024 [1] Clinical Programs - Anixa's breast cancer clinical trial is producing very positive results, exceeding expectations [1] - The company's CAR-T trial for recurrent and resistant ovarian cancer patients is also showing promising results [1] - Both clinical trials are generating significant positive outcomes that will be updated in the upcoming presentation [1]